Zobrazeno 1 - 5
of 5
pro vyhledávání: '"E. E. Tselipanova"'
Publikováno v:
Детские инфекции (Москва), Vol 20, Iss 3, Pp 67-72 (2021)
The relevance of monitoring the course of coronavirus infection COVID-19 in combination with comorbid pathology is obvious, since this new infection with immunopathological pathogenesis is not fully understood.The article presents a clinical case of
Externí odkaz:
https://doaj.org/article/d1cfac5f52a54c1894f2ace6199dd1e6
Autor:
E. E. Tselipanova, E. V. Rusanova
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 0, Iss 42, Pp 66-71 (2016)
Background: A special attention in the treatment of acute respiratory disorders (ARD) in children should be paid to correction of defense mechanisms of the body, including elimination of dysbiotic abnormalities. The use of probiotics, whose mechanism
Externí odkaz:
https://doaj.org/article/8f627dacb1064ae1b77867a6b8e3d78c
Publikováno v:
Doklady Biological Sciences. 507:416-427
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a93c243992d7540c24b0f6fb34ca3fd7
https://doi.org/10.1134/s0012496622060217
https://doi.org/10.1134/s0012496622060217
Publikováno v:
Zhurnal mikrobiologii, epidemiologii i immunobiologii. (2)
Clinical and laboratory evaluation of the preparation Acipol in 45 children greatly susceptible to acute respiratory virus infections (ARVI) was carried out. Simultaneously with the clinical analysis, the study of the microflora of the mucous membran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0d5e4836b2a965d386f1bab0a513e68e
https://pubmed.ncbi.nlm.nih.gov/12886611
https://pubmed.ncbi.nlm.nih.gov/12886611
Autor:
A L, Beliaev, E I, Burtseva, A N, Slepushkin, N A, Beliaeva, N N, Nosik, L A, Lavrukhina, L N, Maksimova, L V, Feklisova, V M, Shibekova, N F, Danina, E E, Tselipanova, S A, Bylinkina, E M, Voĭtsekhovskaia, A A, Sominina
Publikováno v:
Vestnik Rossiiskoi akademii meditsinskikh nauk. (8)
The antiviral drug arbidole reduces influenza and acute respiratory diseases (ARD) in children by 1.5-2 times when given in a dose of 0.1-0.2 g 2-3 or 5 times a week, by making influenza and ARD milder and decreasing their duration by 1.4-2.8 days. U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::747d65b99748e3e395d807f8b52fe8e5
https://pubmed.ncbi.nlm.nih.gov/8963194
https://pubmed.ncbi.nlm.nih.gov/8963194